FDA approved Foundation Medicine’s FoundationOne CDx to be used as a companion diagnostic for Piqray (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
